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Do DNA ploidy and S-phase fraction in primary tumour predict the
response to chemotherapy in metastatic breast cancer?
P Hietanen', C Blomqvist', V-M Wasenius', E Niskanen', K Franssila' and S Nordling2
'Department ofRadiotherapy andOncology, University Central Hospital ofHelsinki, Haartmaninkatu 4, 00290 Helsinki, Finland;
2Department ofPathologv, University ofHelsinki, Haartmaninkatu 3, 00290 Helsinki, Finland.
The relationship between the response to chemotherapy with cyclophosphamide, epirubicin and
fluorouracil as well as the time to progression of metastasised breast cancer and DNA ploidy and S-phase
fraction (SPF) of primary tumours was examined using paraffin-embedded tumour tissue from 81 patients. The
response to chemotherapy was significantly better in patients with tumours with a high SPF, and in addition
the time to progression was longer in the high-SPF group. There was no significant difference when the DNA
ploidy and response to treatment were compared.
Keywords S-phase; response; chemotherapy; breast cancer
The knowledge of prognostic factors in early breast cancer
has grown rapidly in recent years. Both node-negative and
node-positive breast cancer patients contain identifiable sub-
groups with greatly different prognosis (Hedley et al., 1987;
Sigurdsson et al., 1990; Ewers et al., 1991; Clark et al., 1992;
Joensuu and Toikkanen, 1992). Evidence from a large
number of studies indicates an association between high S-
phase fraction (SPF) and a shorter disease-free survival and
overall survival of patients with breast cancer (Hedley et al.,
1987; Kallioniemi et al., 1988; StAl et al., 1989; Toikkanen et
al., 1989; Uyterlinde et al., 1990; Ewers et al., 1991; Joensuu
and Toikkanen, 1992; O'Reilly et al., 1992; Clark et al.,
1993). Patients with aneuploid tumours also tend to have a
worse prognosis than those with diploid tumours (Hedley et
al., 1987; Kallioniemi et al., 1987; StAl et al., 1989; Toik-
kanen et al., 1989; Uyterlinde et al., 1990). In most studies
the SPF and DNA ploidy appear to be independent of
tumour size, nodal status and steroid hormone receptor
status. Owing to the strong association between high SPF,
aneuploidy and histological grade, the independent prognos-
tic significance of SPF and ploidy is sometimes lost when
histological grade is included in a multivariate analysis (Toik-
kanen et al., 1989).
The ability of DNA ploidy or SPF to predict the response
to systemic treatment is a relatively unexplored area. There
are four reports, involving a limited number of patients, on
the ability of flow cytometry (FCM) of fine-needle aspirates
to predict the chemosensitivity of primary breast tumours
(Remvikos et al., 1989, 1993; Brifford et al., 1992; O'Reilly et
al., 1992). Brifford et al. and O'Reilly et al. found a
significantly higher response rate to combination
chemotherapy in aneuploid tumours than in diploid ones.
Although Remvikos et al. did not observe such a significant
difference, a good response to therapy correlated significantly
with a high SPF in all these studies.
In the only study in which the DNA ploidy and SPF ofthe
primary breast tumour were compared with the
chemotherapeutic response of the metastatic disease, no
significant correlation was found (Masters et al., 1987).
Bonetti et al. (1994) found a positive correlation approaching
statistical significance between the proliferative activity of the
primary tumour measured by Ki-67 and the
chemotherapeutic response of the metastatic disease. In the
study of Sulkes et al. (1979) the proliferative activity of the
metastatic disease was determined by tritiated thymidine
labelling index (TLI) in 25 breast cancer patients. TLI was
significantly higher in responders to chemotherapy than in
non-responders.
Correspondence: P Hietanen
Received 4 August 1994; revised 5 January 1995; accepted 5 January
1995
The aim of the present study was to examine whether
DNA ploidy and SPF can predict the response to combina-
tion chemotherapy with cyclophosphamide, epirubicin and
fluorouracil (FEC) and time to progression in metastasised
breast cancer.
Patients and methods
Patients
A total of 173 patients with measurable or evaluable metas-
tatic breast cancer were enrolled in a chemotherapy trial
between November 1987 and January 1991 at the Depart-
ment of Radiotherapy and Oncology of the University Cen-
tral Hospital in Helsinki.
Two randomised groups of patients received the same
monthly dose of 5-fluorouracil (500 mgm-2), epirubicin
(60 mg m2) and cyclophosphamide (500 mg m-') either on a
weekly or on a monthly basis. A total of 158 patients were
evaluable for response. Tumour response was evaluated by
International Union Against Cancer (UICC) criteria
(Hayward et al., 1977). For non-measurable but assessable
lesions outside the skeleton only three categories were used:
complete response (CR), no change (NC) and progressive
disease (PD). The details of the trial methods and results
have been published previously (Blomqvist et al., 1993). The
survival was significantly longer in the group treated once a
month. Formalin-fixed, paraffin-embedded blocks from
primary tumours of 88 patients were available for DNA flow
cytometry. In 83 cases both SPF and DNA ploidy could be
determined. Two of these cases were excluded later because
of wrong diagnosis of advanced disease. The pretreatment
characteristics of this subpopulation were similar to the total
trial population (Table I).
Flow cytometry
A modification of the method of Hedley et al. (1983) was
applied. In brief, two 50-jm-thick sections were treated with
10jgml-' proteinase K (Sigma, St Louis, MO, USA) for
30 min at room temperature. After filtration, the nuclei were
treated with I0 iLg ml'- RNAse and stained with 25jigml-I
ethidium bromide (Sigma) for at least 1 h. The DNA was
determined by FCM (FACScan, Becton Dickinson, Moun-
tain View, CA, USA) using 200 mW excitation at 488 nm,
and the total emission above 560 nm was recorded. As the
staining intensity of fixed nuclei varies from one sample to
another, no internal standard was added. The lowest peak
was assigned a DNA index (DI) value of 1.00 and the DI
values ofother peaks were calculated with this as a reference.
Therefore, possible hypodiploid peaks were identified as dip-SW PS cmu --od-i yi brn crmmr
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loid and the normal diploid peak as hyperdiploid. In breast
cancer hypodiploid tumours are rare. The histograms were
interpreted by one of us (SN) without knowledge of the
clinical outcome. The SPF was calculated either using the
Cellfit program of the FACScan flow cytometer or manually
by a modified rectiinear method (Baisch et al., 1975; Camp-
lejohn et al., 1989) in 83/88 (94%) of the tumours. In four
cases the SPF could not be calculated, in three cases the SPF
could only be calculated using the manual method. If the
tumour was near diploid (DI> 1.20) it was impossible to
separate the two populations and a mean SPF had to be
calculated. If the automatic and the manual methods gave
different results, the lower SPF was chosen. Usually the
manual method gave the lower result, because it was only
applied in those tumours in which it was felt that the
automatic method gave a too high SPF, e.g. when there was
a skewness to the right of the GI peak. Tumours with one
peak were recorded as diploid and those with more than one
peak were considered non-diploid. If there were several
aneuploid stem lines, the tumours were classified as multi-
ploid. There were only two such tumours. The SPF of the
stem line with the highest DI was calculated. Only in one
multiploid tumour could the SPF be evaluated. At least
10000 nuclei from each specimen were analysed.
The median SPF was 4.2% in the diploid and 12.5% in the
non-diploid tumours. Tumours with a SPF equal to or below
the median in either the diploid or the non-diploid popula-
tion were considered to be low SPF, and those with a SPF
above the median were considered to be high SPF.
Statistical methods
Differences in treatment response between diploid and non-
diploid tumours as well as low- and high-SPF tumours were
tested by the Mann-Whitney test. The statistical differencs
between ploidy and SPF groups in time to progression and
survival were tested with the log-rank test.
Results
The response to treatment could be evaluated in 72 (89%)
patients. Reasons for inevaluability were protocol violations
in eight cases and short treatment time in one case. Twenty-
five (35%) patients had DNA diploid and 47 (65%) non-
diploid tumours. Of these non-diploid tumours, two were
multiploid (more than one aneuploid stem line). The time to
progression could be evaluated in 80 patients (99%). One
patient was excluded because of early death. The responses
to treatment in different DNA ploidy and S-phase groups are
shown in Table II.
No significant difference was seen when DNA ploidy and
response to chemotherapy were compared either in all
patients or in the two treatment groups separately. However,
the time to progression was significantly longer in patients
with diploid than in those with non-diploid tumours
(P = 0.05) (Figure 1).
A positive response to either type of chemotherapy was
seen in only 6/34 (18%) patients with low-SPF tumours,
whereas 17/38 (45%) patients with high-SPF tumours showed
Table I Pretreatment characteristics
Mean age (median, range)
ER-positive, n (%)
PgR-positive, n (%)
SPF (%) (median, range)
Diploid tumours, n (%)
Aneuploid tumours (%)
Median SPF in diploid tumours
Median SPF in aneuploid tumours
DFI, months (median, range)
Previous cytotoxic
therapy, n (%)
Number of metastatic sites
<2 (%)
Soft tissue metastases, with or
without bone involvement, n (%)
Bone metastases only, n (%)
Visceral metastases, n (%)
DFI, disease-free interval.
53.1
33/75
25/75
9.4
31/81
50/81
4.2
12.5
25.5
(32.3-72.0)
(44)
(33)
(1-24.9)
(38)
(62)
0
0.
0 (0-131)
10/81 (12)
62/81 (77)
19/81 (24)
13/81 (16)
8/81 (10)
60/81 (74)
0
All
0 5 10 15 20 25 30 35 40
Time to progression (months)
Fugw 1 Time to progression in patients with diploid (-) and
non-diploid (0) tumours.
Table H Responses to treatment in different DNA ploidy and S-phase groups
Treatment outcome
CR PR NC PD
Group n % n % n % n %
All
Diploid 2 8 9 36 5 20 9 36
Aneuploid 3 6 9 19 14 30 21 45 P=0.269
Weekly
Diploid - - 4 40 3 30 3 30
Aneuploid - - 4 17 6 26 13 57 P=0.153
Monthly
Diploid 2 13 5 33 2 13 6 40 P=0.868 Aneuploid 3 13 5 21 8 33 8 33
All
High S-phase 3 8 14 37 11 29 10 26
Low S-phase 2 6 4 12 8 24 20 59
Weekly
High S-phase - - 6 35 6 35 5 29 P=0.042 Low S-phase - - 2 13 3 19 11 69
Monthly
High S-phase 3 14 8 38 5 24 5 24 P=0.081 Low S-phase 2 11 2 11 5 28 9 50
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1 All
0.8
0.6
0.4
0.2
0
0 5 10 15 20 25 30 35 40
Time to progression (months)
Frw 2 Time to progression in the high-SPF (0) and low-SPF
(0) groups in all patients.
a positive response (P = 0.01). Of the patients with low-SPF
tumours, which received weekly treatment, 2/16 (13%) re-
sponded positively compared with 6/17 (35%) in the high-
SPF group (P = 0.04). There was a trend towards longer time
to progression in the high-SPF group (P = 0.07) in all
patients (Figure 2) compared with the low-SPF group, and
especially in those treated on a weekly basis (P = 0.03)
(Figure 3).
The disease-free interval from the diagnosis to the first
recurrence was not significantly different in high- and low-
SPF groups (13.0 and 19.0 months respectively, P=0.10).
The median overall survival after the randomisation to
chemotherapy was not significantly different in low- and
high-SPF groups (16.1 and 16.8 months respectively) or for
diploid and non-diploid tumours (17.0 and 16.1 months
respectively).
An objective regression of advanced breast cancer can be
achieved in approximately 50% of patients receiving
chemotherapy (Blomqvist et al., 1993). Chemotherapeutic
agents are generally more active against cycling than non-
cycling cells in vitro (Drewinko et al., 1981). Numerous
studies have demonstrated a relatively small growth fraction
in most human solid tumours, particularly breast tumours.
Drug resistance is a central problem in cancer treatment, and
it is therefore important to develop reliable criteria for the
selection of those patients who benefit from chemotherapy.
In our study there was no significant difference comparing
the DNA ploidy of the primary tumour and the response,
although there was a non-significant trend towards a better
response in diploid tumours. Previous studies in which DNA
content and the response to chemotherapy have been cor-
related are contradictory. Our findings agree with those of
Masters et al. (1987), the only study in which DNA ploidy of
the primary tumour and the response to chemotherapy of
advanced disease has been correlated. Remvikos et al. (1989),
who correlated the response of the primary tumour to
chemotherapy and DNA ploidy, did not find a significant
difference. However, Brifford et al. (1989) and O'Reilly et al.
(1992) observed a significantly higher response rate to com-
bination chemotherapy in aneuploid than in diploid tumours.
The response rate did not correlate to the DNA ploidy of
1 Weekly
0.8 ,
0.6
0.4
0.2-
00 5 10 15 20 25 30 35 40
Time to progression (months)
Fugwe 3 Time to progression in the high-SPF (0) and low-SPF
() tumours in patients treated on a weekly basis.
the primary tumours in our study, but the time to progres-
sion was significantly longer in patients with diploid tumours
than in those with non-diploid tumours. This may be related
to their less aggressive clinical course rather than due to the
chemotherapy. The overall survival after randomisation did
not differ between these groups.
In the present study the response to chemotherapy was
significantly better in the high-SPF group. There was also a
trend towards longer time to progression in the high-SPF
group, which may be related to the better response to treat-
ment in patients with these tumours, as the disease-free sur-
vival did not differ significantly in these groups. Our finding
agrees with previous reports on improved chemotherapeutic
response rates in primary tumours with high SPF (Osborne,
1989; Remvikos et al., 1989, 1993; O'Reilly et al., 1992;
Spyratos et al., 1992) and in advanced breast cancer, when
primary tumours showed high proliferative activity measured
by Ki-67 (Bonetti et al., 1994) and tumour cell uptake of
tritiated thymidine (Sulkes et al., 1979).
While in our study the tumours of patients treated weekly
showed less response as a whole to chemotherapy, the re-
sponse rate of tumours with a high SPF was significantly
better than that of tumours with a low SPF also in this
group. Niskanen et al. (1993) found that an amplification of
the c-erbB-2 gene predicts a favourable response in patients
receiving chemotherapy on a weekly basis. This may indicate
that patients with tumours with a high proliferation rate may
benefit from a more frequent administration of drugs. The
time to progression was significantly longer in the high-SPF
group treated on a weekly basis, while no clear difference was
seen with the treatment every fourth week. It will be impor-
tant to verify our results in a study with more patients and
with other chemotherapy regimens.
In conclusion, our results indicate that patients with
advanced breast cancer who have primary tumours with a
high SPF respond better to combination chemotherapy than
patients with low-SPF tumours. An assessment of the SPF
may assist in the selection of patients with advanced breast
cancer for chemotherapy. This has to be confirmed in a study
with more patients.
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